Investigation on the heating effects of intra-tumoral injectable magnetic hydrogels (IT-MG) for cancer hyperthermia
Biomedical Physics & Engineering Express · 2025
DOI: 10.1088/2057-1976/adaec6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Physics & Engineering Express, 2025. Verfasst von Hema Brindha Masanam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India. Hauptthemen laut MEDLINE: Hyperthermia, Induced, Hydrogels, Magnetite Nanoparticles, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Capacitive-based radiofrequency (Rf) radiation at 27 MHz offers a non-invasive approach for inducing hyperthermia, making it a promising technique for thermal cancer therapy applications. To achieve focused and site-specific hyperthermia, Rf-responsive materials is required to convert Rf radiation into localized heat efficiently. Nanoparticles capable of absorbing Rf energy and convert into heat for targeted ablation are of critical importance. In this study, we developed and evaluated an Intra-tumoral injectable magnetic hydrogel (IT-MG) composed of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) impregnated in low molecular weight Hyaluronic Acid (HA) forming HA-SPIONs. Our systematic investigation revealed that HA-SPIONs exposed to Rf radiation significantly increased temperature, reaching up to 50 °C. Further testing in tissue-mimicking phantom models also showed consistent heating, with temperatures stabilizing at 43 °C, ideal for localized hyperthermia. The ability of HA-SPIONs to act as an effective localized heating agent when exposed to 27 MHz Rf radiation, reaching apoptosis-inducing temperature, has not been previously reported. In conclusion, synergistic effects of IT-MG in both in-vitro and tumor-mimicking phantom models demonstrate improved and localized hyperthermia, facilitating adjuvant cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, SRM Institute of Science and Technology, Kattankulathur-603203, Tamil Nadu, India.
- School of Biological and Health Systems Engineering, Ira A. Fulton Schools of Engineering, Arizona State University, Tempe, AZ 85281, United States of America.
- Computer Science Engineering, Campbusvile University, Kentucky, KY 42718, United States of America.
- Department of Life Sciences, School of Basic Sciences and Research, Sharda University, Greater Noida 201310, Uttar Pradesh, India.
- Department of Biomedical Engineering, College of Engineering and Applied Science, University of Wisconsin, 3200 North Cramer Street, Milwaukee, WI 53211, United States of America.
- Acrofluidic Innovations Private Limited, Chennai 600 059, Tamil Nadu, India.
ORCID-Profile: Hema Brindha Masanam, Bharath Chandra, Ashwin Kumar Narasimhan
Zitieren
APA
Masanam, H. B., Muthuraman, J., Chandra, B., Kottapalli, V. N. S. M., Chandra, S. S., Gupta, P. K., & Narasimhan, A. K. (2025). Investigation on the heating effects of intra-tumoral injectable magnetic hydrogels (IT-MG) for cancer hyperthermia. Biomedical Physics & Engineering Express. https://doi.org/10.1088/2057-1976/adaec6
Vancouver
Masanam HB, Muthuraman J, Chandra B, Kottapalli VNSM, Chandra SS, Gupta PK, et al. Investigation on the heating effects of intra-tumoral injectable magnetic hydrogels (IT-MG) for cancer hyperthermia. Biomedical Physics & Engineering Express. 2025. doi:10.1088/2057-1976/adaec6
BibTeX
@article{Masanam2025,
author = {Masanam, Hema Brindha and Muthuraman, Janani and Chandra, Bharath and Kottapalli, Venkata Naga Sundara Mahesh and Chandra, Sai Sarath and Gupta, Piyush Kumar and Narasimhan, Ashwin Kumar},
title = {Investigation on the heating effects of intra-tumoral injectable magnetic hydrogels (IT-MG) for cancer hyperthermia},
journal = {Biomedical Physics & Engineering Express},
year = {2025},
doi = {10.1088/2057-1976/adaec6}
}
EUVIMED